{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:12:55Z","timestamp":1786119175108,"version":"build-2736575974"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/cco.0b013e32830b61ac","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:53:39Z","timestamp":1236272019000},"page":"502-508","source":"Crossref","is-referenced-by-count":10,"title":["Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation"],"prefix":"10.1097","volume":"20","author":[{"given":"Paul M","family":"Barr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.bmt.1702336","article-title":"Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)","volume":"25","author":"Voso","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V97.2.404","article-title":"High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial","volume":"97","author":"Horning","year":"2001","journal-title":"Blood"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s002770100321","article-title":"Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?","volume":"80","author":"Seyfarth","year":"2001","journal-title":"Ann Hematol"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2002-02-0621","article-title":"High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"100","author":"Ladetto","year":"2002","journal-title":"Blood"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2006.00685.x","article-title":"Late nonrelapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990\u20132003","volume":"77","author":"Jantunen","year":"2006","journal-title":"Eur J Haematol"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bmt.1705547","article-title":"Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?","volume":"39","author":"Hake","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.2005.05.158","article-title":"Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"23","author":"Brown","year":"2005","journal-title":"J Clin Oncol"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","article-title":"Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia","volume":"24","author":"Kalaycio","year":"2006","journal-title":"J Clin Oncol"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","article-title":"Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission","volume":"13","author":"Brown","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.leu.2404346","article-title":"Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial","volume":"20","author":"Ladetto","year":"2006","journal-title":"Leukemia"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2004-12-4689","article-title":"High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver","volume":"106","author":"Lavoie","year":"2005","journal-title":"Blood"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbmt.2007.06.003","article-title":"Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study","volume":"13","author":"Majhail","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190600570958","article-title":"High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed\/refractory lymphoma","volume":"47","author":"Oyan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/cncr.22911","article-title":"The impact of pre and posttransplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation","volume":"110","author":"Filmont","year":"2007","journal-title":"Cancer"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/10428190701583983","article-title":"The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation","volume":"48","author":"Keeney","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2141.2006.06088.x","article-title":"Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma","volume":"133","author":"Holtan","year":"2006","journal-title":"Br J Haematol"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2006.06323.x","article-title":"Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies","volume":"135","author":"Fanning","year":"2006","journal-title":"Br J Haematol"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/10428190500126380","article-title":"The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma","volume":"46","author":"Yoong","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2007.04.001","article-title":"Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation","volume":"13","author":"Ninan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1705708","article-title":"Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma","volume":"40","author":"Tomblyn","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705763","article-title":"Patients mobilizing large numbers of CD34+ cells (\u2018super mobilizers\u2019) have improved survival in autologous stem cell transplantation for lymphoid malignancies","volume":"40","author":"Bolwell","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/stemcells.2005-0613","article-title":"Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells","volume":"25","author":"Witzens-Harig","year":"2007","journal-title":"Stem Cells"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2141.2002.03256.x","article-title":"A sequence of immuno-chemotherapy with rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and nontoxic treatment for advanced follicular and mantle cell lymphoma","volume":"116","author":"Lazzarino","year":"2002","journal-title":"Br J Haematol"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni","year":"2000","journal-title":"Blood"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2005.05827.x","article-title":"Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device","volume":"132","author":"van Heeckeren","year":"2006","journal-title":"Br J Haematol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bmt.1705849","article-title":"Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma","volume":"40","author":"Kang","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00277-006-0157-6","article-title":"Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma","volume":"85","author":"Hess","year":"2006","journal-title":"Ann Hematol"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","article-title":"Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma","volume":"23","author":"Vose","year":"2005","journal-title":"J Clin Oncol"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"J Clin Oncol"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/14796694.3.1.19","article-title":"AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent","volume":"3","author":"Cashen","year":"2007","journal-title":"Future Oncol"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"R57-4-20210128","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"R58-4-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"R60-4-20210128","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R61-4-20210128","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R62-4-20210128","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"van Besien","year":"1998","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32830b61ac","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:30Z","timestamp":1786038030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200809000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32830b61ac","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}